Inflammatory bowel diseases (IBD) manifest not only in the gastrointestinal (GI) tract, but also affect joints, skin, eyes, liver, lung, and pancreas. Up to half of patients with IBD have extraintestinal manifestations (EIMs) of IBD. Therapies for intestinal inflammation are not sufficient to treat EIMs such as anterior uveitis, ankylosing spondylitis, and primary sclerosing cholangitis (PSC), which usually occur independent of disease flares. In the October issue of Gastroenterology, Gerhard Rogler et al review the epidemiology, pathophysiology, clinical presentation, and treatment of EIMs in patients with IBD.
Trending
- Digital self-management programme for pain, fatigue and faecal incontinence in inflammatory bowel disease: cost-effectiveness analysis of the IBD-BOOST randomised controlled trial (BMJ)
- Clinicians Encouraged to ‘See C. diff Differently’ as Diagnostics, Resistance Patterns, and Therapeutic Tools Shift (GI & Endoscopy News)
- AGA, ACG Express Concerns About New American Cancer Society Recommendations (GI & Endoscopy News)
- In vitro development of the Autonomous Colonoscope Robot System (ACRS) for fully automated colonoscope insertion (Nature)
- Zobair Younossi, MD, on Global Consensus Recommendations for MASLD/MASH (HMP Global Learning Network )
- Recommending Blood Tests for CRC Without Guardrails Risks Confusion (MedPage Today)
- Gut Microbiome Could Remain Disrupted For Over a Decade After Polyp Removal (ScienceAlert)
- Why physician is not the same as provider (KevinMD)
